Business
Amended: Voyageur Pharmaceuticals Ltd. Announces Final Closing of Increased Private Placement
(TheNewswire) C algary, A B - TheNewswire - January 23 , 2023 - V...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Amended: Voyageur Pharmaceuticals Ltd. Announces Final Closing of Increased Private Placement \n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n C\n \n \n algary, A\n \n \n B - TheNewswire -\n \n \n January\n \n \n 23\n \n \n ,\n2023 -\n \n \n Voyageur Pharmaceuticals Ltd.\n \n \n (TSXV:VM)\n(USA:VYYRF)\n \n \n (the \"\n \n \n Company\n \n \n \" or\n\"\n \n \n Voyageur\n \n \n \") announces that, further to its news releases dated\nDecember 8 and 23, 2022 and January 12 and 20, 2023, the use of\nproceeds with respect to its increased non-brokered private placement\nof units of the Company (\"\n \n \n Units\n \n \n \") at a price of $0.07 per Unit (the\n\"\n \n \n Offering\n \n \n \"), were incorrectly totalled. The gross proceeds\nreceived by Voyageur from the Offering will be used to advance\nVoyageur’s project in the following order:\n \n \n \n \n \n \n \n Commissions & Offering Costs\n \n \n \n \n \n \n $60,000\n \n \n \n \n \n \n \n \n SmoothX & Corporate Marketing\n \n \n \n \n \n \n $250,000\n \n \n \n \n \n \n \n \n FDA EMA Testing\n \n \n \n \n \n \n $340,000\n \n \n \n \n \n \n \n \n Legal\n \n \n \n \n \n \n $50,000\n \n \n \n \n \n \n \n \n Auditing fees\n \n \n \n \n \n \n $60,000\n \n \n \n \n \n \n \n \n Frances Creek 2,000 tonne engineering\n \n \n \n \n \n \n $60,000\n \n \n \n \n \n \n \n \n Deposit- Pharma GMP facility purchase -Due Diligence-\n100% refundable\n \n \n \n \n \n \n $100,000\n \n \n \n \n \n \n \n \n Corporate G&A\n \n \n \n \n \n \n $279,949.46\n \n \n \n \n \n \n \n \n Total\n \n \n \n \n \n \n $1,199,949.46\n \n \n \n \n \n \n \n Completion of the Offering is subject to regulatory\napproval including, but not limited to, the approval of the TSX\nVenture Exchange.\n \n \n \n \n About Voyageur\n \n \n \n \n Voyageur is a Canadian public company listed on the\nTSXV under the trading symbol VM. Voyageur is focused on the\ndevelopment of barium and iodine Active Pharmaceutical Ingredients\n(“API”) and high-performance cost-effective imaging contrast\nagents for the medical imaging marketplace. Voyageur’s goal is to\nfully integrate the barium and iodine contrast market by producing its\nown minerals of barium and iodine. The business plan is to initially\ngenerate cash flow from operations using third party GMP\npharm...